The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment†
Open accessAbstract
Cholangiocarcinoma (CCA) is an epithelial cancer originating from the bile ducts with features of cholangiocyte differentiation.1 CCA is the second most common primary hepatic malignancy, and epidemiologic studies suggest its incidence is increasing in Western countries.2 Advanced CCA has a devastating prognosis, with a median survival of <24 months.3 The only curative therapy is surgical extirpation or liver transplantation, but unfortunately the majority of patients present with advanced stage disease, which is not amenable to surgical therapies. Anatomically, CCA is classified into extrahepatic and intrahepatic forms of the disease. The extrahepatic form is more common, accounting for 80% to 90% of CCAs. It is further divided into proximal or perihilar and distal subsets depending on the location of the cancer within the extrahepatic biliary system. Perihilar disease is also frequently referred to as a Klatskin tumor. Three different growth patterns of extrahepatic CCA can be observed: (1) periductal infiltrating, (2) papillary or intraductal, and (3) mass forming.4 Intrahepatic CCA typically presents as an intrahepatic mass. In addition to their distinct morphology and clinical presentations, intrahepatic and extrahepatic CCAs differ in etiopathogenesis, molecular signatures, and management. In the last several years there have been significant new insights into the molecular pathogenesis of CCA. New diagnostic and therapeutic modalities have also been developed, resulting in improved detection rates and outcomes. In addition, we have now entered the era of targeted therapies for human cancers. Therefore, it is timely and topical to review these advances with a focus on promising targeted therapies for this disease. An additional goal is to stimulate further interest in this disease with the hope of improving outcomes for this still highly lethal malignancy. Hepatobiliary malignancies account for 13% of the 7.6 million annual cancer-related deaths worldwide and for 3% of the 560,000 annual cancer-related deaths in the United States. CCA accounts for 10% to 20% of the deaths from hepatobiliary malignancies. The prevalence of CCA shows a wide geographic variability, with the highest rates in Asia and the lowest in Australia.5 In the United States, the incidence of CCA has been reported to be 0.95/100,000 for intrahepatic forms and 0.82/100,000 for extrahepatic forms of the disease.5 Its prevalence in different racial and ethnic groups is heterogeneously distributed, with the highest age-adjusted prevalence in Hispanics (1.22/100,000) and the lowest in African Americans (0.17-0.5/100,000).6 In the last 4 decades, United States incidence rates of intrahepatic CCA have increased by 165%, whereas the extrahepatic CCA incidence has remained stable.7, 8 The significant increase in age-adjusted incidence of intrahepatic CCA was confirmed after correction for a prior misclassification of hilar CCA as intrahepatic CCA.2 Similarly, increasing incidence rates of intrahepatic CCA have also been reported in Western Europe and Japan.9, 10 The cause for the increasing incidence has not been identified. We speculate that increased lipid mediators such as oxysterols may contribute to the current increased incidence in Western societies.11 In Western nations, the median age at presentation is >65 years, and it is only rarely diagnosed in patients <40 years of age except in patients with primary sclerosing cholangitis (PSC).5 There is a slight male predominance for CCA. CCA, cholangiocarcinoma; CT, computed tomography; DIA, digital image analysis; EGFR, epidermal growth factor receptor; ERCP, endoscopic retrograde cholangiopancreatography; FISH, fluorescence in situ hybridization; IL-6, interleukin-6; iNOS, inducible nitric oxide synthase; MAPK, mitogen-activated protein kinase; MRCP, magnetic resonance cholangiopancreatography; MRI, magnetic resonance imaging; PDT, photodynamic therapy; PET, positron emission tomography; PSC, primary sclerosing cholangitis; PTC, percutaneous transhepatic cholangiography; RNOS, reactive nitrogen oxide species; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand. In the majority of cases, the etiology of CCA remains obscure. However, several conditions associated with inflammation and cholestasis have been identified as risk factors for CCA (Table 1). PSC is a common risk factor. The prevalence of CCA in this condition is 5% to 15%, and the annual incidence rate is 0.6% to 1.5%.12, 13 The majority of PSC patients who develop CCA do so within the first 2.5 years following the diagnosis of PSC.12, 13 Thus, the symptomatic patient who presents with their first diagnosis of PSC should be carefully screened for CCA. Hepatobiliary flukes—especially the species Opisthorchis viverrini and Clonorchis sinenesis—are risk factors for CCA.14 They are endemic in portions of East Asia, where ingesting undercooked fish is common. Several case–control studies as well as animal models have confirme
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Han, C. L., & Wu, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500562200 · Cited by 153
RetractedSpecific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Extension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma
Jarnagin, W. R., Fong, Y., DeMatteo, R. P., Gonen, M., Burke, E. C., Bodniewicz, J., Youssef, M., Klimstra, D., & Blumgart, L. H. (2001) · Annals of Surgery · doi:10.1097/00000658-200110000-00010 · Cited by 1,347
Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution
DeOliveira, M. L., Cunningham, S. C., Cameron, J. L., Kamangar, F., Winter, J. M., Lillemoe, K. D., Choti, M. A., Yeo, C. J., & Schulick, R. D. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000251366.62632.d3 · Cited by 1,300
Cholangiocarcinoma: A Spectrum of Intrahepatic, Perihilar, and Distal Tumors
Nakeeb, A., Pitt, H. A., Sohn, T. A., Coleman, J., Abrams, R. A., Piantadosi, S., Hruban, R. H., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (1996) · Annals of Surgery · doi:10.1097/00000658-199610000-00005 · Cited by 1,187
The Epidemiology of Cholangiocarcinoma
Shaib, Y., & El-Serag, H. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828889 · Cited by 1,132
MAKUUCHI, M., Thai, B. L., Takayasu, K., Takayama, T., Kosuge, T., Gunvén, P., Yamazaki, S., Hasegawa, H., & Ozaki, H. (1990) · PubMed · Cited by 1,120
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Cited by
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Self-citationPathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,307
Self-citationPrimary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Khan, S. A., Davidson, B. R., Goldin, R. D., Heaton, N., Karani, J., Pereira, S. P., Rosenberg, W. M. C., Tait, P., Taylor-Robinson, S. D., Thillainayagam, A. V., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301748 · Cited by 797
Clinical diagnosis and staging of cholangiocarcinoma
Blechacz, B., Komuta, M., Roskams, T., & Gores, G. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.131 · Cited by 747
Self-citationSia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., Peix, J., Sole, M., Tovar, V., Alsinet, C., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.001 · Cited by 575
Welzel, T. M., Graubard, B. I., Zeuzem, S., El-Serag, H. B., Davila, J. A., & McGlynn, K. A. (2011) · Hepatology · doi:10.1002/hep.24397 · Cited by 543
Banales, J. M., Huebert, R. C., Karlsen, T., Strazzabosco, M., LaRusso, N. F., & Gores, G. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0125-y · Cited by 517
Self-citationChan-on, W., Nairismägi, M.-L., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., Lim, K. H., McPherson, J. R., Cutcutache, I., Heng, H. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2806 · Cited by 497
Epidemiology of cholangiocarcinoma: An update focusing on risk factors
Shin, H., Oh, J., Masuyer, E., Curado, M., Bouvard, V., Fang, Y., Wiangnon, S., Sripa, B., & Hong, S. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01458.x · Cited by 454
Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research
Chen, X., & Calvisi, D. F. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.002 · Cited by 434
Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., et al. (2013) · Oncogene · doi:10.1038/onc.2012.315 · Cited by 399
Braconi, C., Huang, N., & Patel, T. (2010) · Hepatology · doi:10.1002/hep.23381 · Cited by 376
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Kendall, T., Verheij, J., Gaudio, E., Evert, M., Guido, M., Goeppert, B., & Carpino, G. (2019) · Liver International · doi:10.1111/liv.14093 · Cited by 350
Izquierdo-Sanchez, L., Lamarca, A., La Casta, A., Buettner, S., Utpatel, K., Klümpen, H.-J., Adeva, J., Vogel, A., Lleo, A., Fabris, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.010 · Cited by 349
Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes
Sekiya, S., & Suzuki, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63065 · Cited by 348
Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos
Sripa, B., Bethony, J. M., Sithithaworn, P., Kaewkes, S., Mairiang, E., Loukas, A., Mulvenna, J., Laha, T., Hotez, P. J., & Brindley, P. J. (2011) · Acta Tropica · doi:10.1016/j.actatropica.2010.07.006 · Cited by 347
Karakatsanis, A., Papaconstantinou, I., Gazouli, M., Lyberopoulou, A., Polymeneas, G., & Voros, D. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.21864 · Cited by 345
Vilana, R., Forner, A., Bianchi, L., García-Criado, Á., Rimola, J., de Lope, C. R., Reig, M., Ayuso, C., Brú, C., & Bruix, J. (2010) · Hepatology · doi:10.1002/hep.23600 · Cited by 318
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Graham, R. P., Barr Fritcher, E. G., Pestova, E., Schulz, J., Sitailo, L. A., Vasmatzis, G., Murphy, S. J., McWilliams, R. R., Hart, S. N., Halling, K. C., et al. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.03.014 · Cited by 313
Self-citationClassification, Diagnosis, and Management of Cholangiocarcinoma
Razumilava, N., & Gores, G. J. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.09.009 · Cited by 312
Self-citationSurvey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Gu, T.-L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V., Wang, Y., Deng, G., Zhu, L., Tan, Z., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015640 · Cited by 307
Rimola, J., Forner, A., Reig, M., Vilana, R., de Lope, C. R., Ayuso, C., & Bruix, J. (2009) · Hepatology · doi:10.1002/hep.23071 · Cited by 298
Selaru, F. M., Olaru, A. V., Kan, T., David, S., Cheng, Y., Mori, Y., Yang, J., Paun, B., Jin, Z., Agarwal, R., et al. (2009) · Hepatology · doi:10.1002/hep.22838 · Cited by 286
Self-citationThe Pathology and Genetics of Metastatic Pancreatic Cancer
Yachida, S., & Iacobuzio-Donahue, C. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.3.413 · Cited by 269
Nf2 /Merlin controls progenitor homeostasis and tumorigenesis in the liver
Benhamouche, S., Curto, M., Saotome, I., Gladden, A. B., Liu, C.-H., Giovannini, M., & McClatchey, A. I. (2010) · Genes & Development · doi:10.1101/gad.1938710 · Cited by 269
Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma
Farges, O., Regimbeau, J. M., Fuks, D., Le Treut, Y. P., Cherqui, D., Bachellier, P., Mabrut, J. Y., Adham, M., Pruvot, F. R., & Gigot, J. F. (2013) · Journal of British Surgery · doi:10.1002/bjs.8950 · Cited by 263
Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids
Artegiani, B., van Voorthuijsen, L., Lindeboom, R. G. H., Seinstra, D., Heo, I., Tapia, P., López-Iglesias, C., Postrach, D., Dayton, T., Oka, R., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.017 · Cited by 218
Navaneethan, U., Njei, B., Venkatesh, P. G. K., Vargo, J. J., & Parsi, M. A. (2014) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.11.001 · Cited by 146
Ruiz, A., Lemoinne, S., Carrat, F., Corpechot, C., Chazouillères, O., & Arrivé, L. (2014) · Hepatology · doi:10.1002/hep.26620 · Cited by 144
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
Paillet, J., Plantureux, C., Lévesque, S., Le Naour, J., Stoll, G., Sauvat, A., Caudana, P., Tosello Boari, J., Bloy, N., Lachkar, S., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200853 · Cited by 41
Gandhy, S. U., Casak, S. J., Mushti, S. L., Cheng, J., Subramaniam, S., Zhao, H., Zhao, M., Bi, Y., Liu, G., Fan, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1042 · Cited by 25
Metadata
- Authors
- Blechacz, B., & Gores, G. J.
- Venue
- Hepatology
- Published
- 2008-07
- Volume
- 48
- Issue
- 1
- Pages
- 308-321
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2035515971
- Cited by
- 681
- References
- 154
- FWCI
- 39.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.